( ietin receptor activator is thefirst ...)Mircera Effective in Stabilising Haemoglobin Levels in Elderly,Patients With Kidney Disease on Dialysis,Health

ietin receptor activator, is the first of a new class of long-acting chemically synthesized erythropoiesis-stimulating agents (ESAs) having reached regulatory review that could represent a significant advance in renal anaemia management. It is in development for the treatment of renal anaemia in chronic kidney disease (CKD) patients on dialysis or not on dialysis. The largest clinical program ever undertaken in renal anaemia has shown that MIRCERA provides predictable and stable haemoglobin management for all CKD patients with up to once-monthly dosing. This innovative agent is currently being reviewed by health authorities in the EU, USA, Switzerland, Canada and Australia.

Notes to Editors:

1. Renal anaemia is caused when the kidneys fail to stimulate the production of red blood cells, which transport the oxygen-carrying protein, haemoglobin, throughout the body. Renal anaemia is present in the early stages of CKD and becomes increasingly common and more severe and more common as the disease progresses. In fact, as patients reach end-stage renal disease, more than 90 per cent(vi)(vii), (viii), of them will be affected by renal anaemia.

2. Current European (EBPG) and US (NKF- K/DOQI) guidelines recommend doctors target specific ranges in treating renal anaemia.

About Roche

For more information, visit www.roche.com.

(i) Lysaght MJ., Maintenance dialysis population dynamics: current trends and long-term implications. Journal of the American Society of Nephrology. 2002. 13: S37-S40.

(ii) Medscape Medical News "Care of ESRD Patients Could be Better: New Approaches Warranted" February 21, 2007

(iii) Collins et al, Excerpts from the Unites States Renal Data System 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. American Journal of Kidney Diseases. Vol 45, No 1, Suppl 1, January 2005

    (iv) European Best Practice Guideline
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Data Analyses Outline Efficacy and Safety of Mircera for the
Treatment of Renal Anemia Associated With Chronic Kidney Disease
2. New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility
3. Eurands Zentase Effective in Treating Exocrine Pancreatic
Insufficiency, Studies Show
4. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid
Arthritis
5. Gabapentin Shown Effective for Fibromyalgia Pain
6. ApoCells Cancer Predictive Index Helps Oncologists Select the Most
Effective Targeted Drug Therapy
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well
Tolerated in Phase 3 Study
8. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine
or Vinorelbine in Treating Non-Small Cell Lung Cancer
9. Soliris Effective in PNH Patients With History of Aplastic Anemia
and Myelodysplastic Syndromes
10. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and
Effective in Colorectal Cancer with Liver Metastases
11. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer
Study